growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Mandatory minimums === The Anti-Drug Abuse Act of 1986 established a 100-1 sentencing disparity for the possession of crack or powder cocaine. Possession of 500 g of powder cocaine triggered a five-year mandatory minimum sentence, but it took possession of 5 g of crack cocaine to trigger the same mandatory minimum penalty. In addition, the Anti-Drug Abuse Act of 1988 established a one-year mandatory minimum penalty for simple possession of crack cocaine, which made crack cocaine the only controlled substance for which a first possession offense triggered a mandatory minimum penalty. A 1992 study found that mandatory minimum sentencing caused blacks and Hispanics to receive more-severe sentences than their white counterparts from 1984 to 1990. In 1995, the United States Sentencing Commission delivered a report to Congress concluding that because 80% of crack offenders were black, the 100–1 disparity disproportionately affected minorities. It recommended for the crack-powder sentencing ratio to be amended, and other sentencing guidelines to be re-evaluated. Its recommendations were rejected by Congress. By contrast, certain authors have pointed out that the Congressional Black Caucus backed the Anti-Drug Abuse Act of 1986, which implied that that law could not be racist. In 2010, Congress passed the Fair Sentencing Act, which reduced the sentencing disparity between crack and powder cocaine from 100–1 to 18–1. The mandatory minimum penalty was amended to take effect for possession of crack cocaine in excess of 28 g.
=== Cuban opposition === On 6 February, El País conducted interviews with various Cuban dissidents, including José Daniel Ferrer, Manuel Cuesta Morúa, and María Payá Acevedo. Their reactions were a mix of hope and warning against manipulations, including views that the Cuban government could cease talks when it stabilizes itself. On 22 May, Cuban opposition leader Ferrer claimed that there is no doubt that the communist regime will end by the end of 2026.
== Clinical features == The disease caused by infection with this parasite is known as rangeliosis. In Brazil it is also known as nambi-uvú (bleeding ears), peste de sangue (bleeding plague) and febre amarela dos cães (yellow fever of dogs).
Sources: en.wikipedia.org
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
== History == It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. On 4 July 2011, the European Medicines Agency (EMA) approved a paediatric investigation plan and granted both a deferral and a waiver for canagliflozin (EMEA-001030-PIP01-10) in accordance with EC Regulation No. 1901/2006 of the European Parliament and of the council. It was approved for medical use in the European Union in November 2013. Canagliflozin was approved by the FDA on 29 March 2013, and became the first SGLT2 inhibitor in the United States. Canagliflozin was approved for medical use in Australia in September 2013.
ATP : NADH+H+ and ATP : FADH2 ratios during the oxidative phosphorylation appear to be not 3 and 2, but 2.5 and 1.5 respectively. Unlike in the substrate-level phosphorylation, the stoichiometry here is difficult to establish. ATP synthase produces 1 ATP / 3 H+. However the exchange of matrix ATP for cytosolic ADP and Pi (antiport with OH− or symport with H+) mediated by ATP–ADP translocase and phosphate carrier consumes 1 H+ / 1 ATP as a result of regeneration of the transmembrane potential changed during this transfer, so the net ratio is 1 ATP : 4 H+. The mitochondrial electron transport chain proton pump transfers across the inner membrane 10 H+ / 1 NADH+H+ (4 + 2 + 4) or 6 H+ / 1 FADH2 (2 + 4). So the final stoichiometry is 1 NADH+H+ : 10 H+ : 10/4 ATP = 1 NADH+H+ : 2.5 ATP 1 FADH2 : 6 H+ : 6/4 ATP = 1 FADH2 : 1.5 ATP ATP : NADH+H+ coming from glycolysis ratio during the oxidative phosphorylation is 1.5, as for FADH2, if hydrogen atoms (2H++2e−) are transferred from cytosolic NADH+H+ to mitochondrial FAD by the glycerol phosphate shuttle located in the inner mitochondrial membrane. 2.5 in case of malate-aspartate shuttle transferring hydrogen atoms from cytosolic NADH+H+ to mitochondrial NAD+ So finally we have, per molecule of glucose
Sources: en.wikipedia.org
=== Urinary glucose testing === Women with GDM may have high glucose levels in their urine (glucosuria). Although dipstick testing is widely practiced, it performs poorly, and discontinuing routine dipstick testing has not been shown to cause underdiagnosis where universal screening is performed. Increased glomerular filtration rates during pregnancy contribute to some 50% of women having glucose in their urine on dipstick tests at some point during their pregnancy. Glomerular filtration rates increase during pregnancy due to an increase in blood volume to support the fetus. The sensitivity of glucosuria for GDM in the first two trimesters is only around 10%, and the positive predictive value is around 20%.
== Antimicrobial peptides == Antimicrobial Peptides (AMPs) have gained attention because they are much less susceptible to the development of microbial resistance. Other antibiotics may be susceptible to bacterial resistance, like multi-resistant staphylococcus aureus (MRSA) which is known as a common relic in the healthcare industry while other bacterial strains have become more of a concern for waste water treatment in local rivers or bays. AMPs can be functionalized onto a surface by either chemical or physical attachment. AMPs can be physically attached by using oppositely charged polymeric layers and sandwiching the polypeptide between them. This may be repeated to achieve multiple layers of AMPs for the recurring antibacterial activity. There are a few drawbacks to this mechanism. Assembly thickness and polymer-peptide interactions can affect the diffusion of peptide to bacterial contact. Further research should be carried out to determine the effectiveness of the adsorption technique. However, the chemical attachment of AMPs is also widely studied. AMPs can be covalently bound to a surface, which minimizes the "leaching effect" of peptides. The peptide is typically attached by a very exergonic chemical reaction, thus forming a very stable antimicrobial surface. The surface can be functionalized first with a polymer resin such as polyethylene glycol (PEG). Recent research has focused on producing synthetic polymers and nanomaterials with similar mechanisms of action to endogenous antimicrobial peptides.
Marxism–Leninism is a communist ideology that became the largest faction of the communist movement following the October Revolution. It was the predominant ideology of most communist governments in the 20th century. It was developed in the Soviet Union by Joseph Stalin and drew on Bolshevism, Leninism, and Classical Marxism. It was the state ideology of the Soviet Union, Soviet satellite states in the Eastern Bloc, and various countries in the Non-Aligned Movement and Third World during the Cold War, as well as the Communist International. It is the ideology of the ruling parties of China, Cuba, Laos, and Vietnam, as well as other communist parties. The state ideology of North Korea is derived from Marxism–Leninism. Marxism–Leninism holds that a two-stage communist revolution is needed to replace capitalism. A vanguard party, organized through democratic centralism, seizes power on behalf of the proletariat and establishes a one-party communist state. The state controls the means of production, suppresses opposition, counter-revolution, and the bourgeoisie, and promotes Soviet collectivism, to pave the way for a communist society that is classless and stateless. After Lenin's death in 1924, Marxism–Leninism became a distinct movement in the Soviet Union when Stalin and his supporters gained control of the Communist Party of the Soviet Union (CPSU). It rejected the notion among Western Marxists of world revolution as a prerequisite for building socialism, in favour of the concept of socialism in one country.
== Discovery and naming == The name renin = ren + -in, "kidney" + "compound". The most common pronunciation in English is (long e); (short e) is also common, but using allows one to reserve for rennin. Renin was discovered, characterized, and named in 1898 by Robert Tigerstedt, Professor of Physiology, and his student, Per Bergman, at the Karolinska Institute in Stockholm.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.